21:02 , Jun 6, 2019 |  BC Innovations  |  Emerging Company Profile

Scipher: decoding drug response from protein interactions

To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction maps into its machine learning-based analyses of patient gene expression data to spotlight pathologically relevant markers. According to Scipher Medicine Corp. CEO...
13:27 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Genitourinary

INDICATION: Genitourinary Patient sample and non-human primate studies suggest inhibiting sFLT1 could help treat preeclampsia. In placental tissue samples from patients, sFLT1 mRNA levels were higher than in samples from healthy volunteers. In a baboon...
19:20 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Patient sample and mouse studies suggest liver-specific ROCK1 inhibition could help treat non-alcoholic fatty liver disease (NAFLD). In 10 NAFLD patients, liver levels of ROCK1 were higher than in nine patients with...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
20:09 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; renal

INDICATION: Lupus; renal damage Patient sample and mouse studies suggest inhibiting CAMK4 could help treat lupus nephritis, focal segmental glomerulosclerosis (FSGS) and other podocytopathies. In kidney samples from lupus nephritis and FSGS patients, podocyte levels...
18:09 , Jun 22, 2018 |  BC Week In Review  |  Company News

NIH ends funding for alcohol study

NIH said it will stop funding the Moderate Alcohol and Cardiovascular Health (MACH) study after concluding that NIH employees violated agency policies to secure its funding and potentially biased its design towards the alcohol industry....
23:41 , Jun 15, 2018 |  BC Extra  |  Politics & Policy

NIH pulls funding from compromised alcohol/CV health trial

NIH said it will stop funding the Moderate Alcohol and Cardiovascular Health (MACH) study after concluding that NIH employees violated agency policies to secure its funding and potentially biased its design towards the alcohol industry....
21:44 , Mar 22, 2018 |  BC Innovations  |  Emerging Company Profile

Hatching antibodies

OstriGen Inc. is developing polyclonal ostrich antibodies as oral therapies for cholera and other GI tract diseases that are designed to be as effective as existing mammalian antibodies while being produced at much lower costs....
17:34 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Block coagulation Mouse studies suggest that ANGPT1 could help treat disseminated intravascular coagulation (DIC) associated with sepsis. In lipopolysaccharide (LPS)-treated human umbilical vein endothelial cells (HUVECs), ANGPT1 decreased levels of clotting factors compared with...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...